- Home
- OLMA vs UPB Comparison
OLMA vs UPB Comparison
Compare OLMA & UPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OLMA
- UPB
- Stock Information
- Founded
- OLMA 2006
- UPB 2021
- Country
- OLMA United States
- UPB United States
- Employees
- OLMA N/A
- UPB N/A
- Industry
- OLMA Biotechnology: Pharmaceutical Preparations
- UPB
- Sector
- OLMA Health Care
- UPB
- Exchange
- OLMA Nasdaq
- UPB NYSE
- Market Cap
- OLMA 383.1M
- UPB 457.2M
- IPO Year
- OLMA 2020
- UPB 2024
- Fundamental
- Price
- OLMA $4.99
- UPB $7.98
- Analyst Decision
- OLMA Strong Buy
- UPB Strong Buy
- Analyst Count
- OLMA 4
- UPB 4
- Target Price
- OLMA $28.33
- UPB $56.50
- AVG Volume (30 Days)
- OLMA 1.0M
- UPB 245.5K
- Earning Date
- OLMA 03-10-2025
- UPB 03-04-2025
- Dividend Yield
- OLMA N/A
- UPB N/A
- EPS Growth
- OLMA N/A
- UPB N/A
- EPS
- OLMA N/A
- UPB N/A
- Revenue
- OLMA N/A
- UPB $2,207,000.00
- Revenue This Year
- OLMA N/A
- UPB N/A
- Revenue Next Year
- OLMA N/A
- UPB N/A
- P/E Ratio
- OLMA N/A
- UPB N/A
- Revenue Growth
- OLMA N/A
- UPB 82.10
- 52 Week Low
- OLMA $4.60
- UPB $6.65
- 52 Week High
- OLMA $16.62
- UPB $29.46
- Technical
- Relative Strength Index (RSI)
- OLMA 38.98
- UPB N/A
- Support Level
- OLMA $4.94
- UPB N/A
- Resistance Level
- OLMA $5.34
- UPB N/A
- Average True Range (ATR)
- OLMA 0.42
- UPB 0.00
- MACD
- OLMA -0.03
- UPB 0.00
- Stochastic Oscillator
- OLMA 11.39
- UPB 0.00
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
About UPB UPSTREAM BIO INC
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases.